Trodelvy

(Sacituzumab govitecan)

Trodelvy

Drug updated on 11/15/2023

Dosage FormInjection (intravenous: 180 mg lyophilized powder in single-dose vial)
Drug ClassTrop-2-directed antibody and topoisomerase inhibitor conjugate
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
  • For the treatment of adult patients with Unresectable locally advanced or metastatic hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrinebased therapy and at least two additional systemic therapies in the metastatic setting
  • For the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PDL1) inhibitor